Opentrons Labworks has raised $40 million from a Series E financing round led by healthcare investor Avego, with additional investment from BroadOak Capital Partners. The company has said that it plans to use the capital to scale its robotics, software, and data infrastructure tools.
Specifically, the funds will support the company’s efforts to design artificial intelligence and robotics systems that work together to design, execute, and learn from scientific experiments. This includes investing in AI-driven experimental execution, extending its automation capabilities, and expanding into new markets and geographies.
Additionally, the funds will allow Opentrons to enable faster protocol development through its software and AI, expand capabilities across its robots and instruments, and provide deeper integration of its tools into the broader lab automation ecosystem.
“Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data,” said James Flexner, managing partner at Avego. “We see a significant opportunity for autonomous science to converge around Opentrons’ platform.” James Atwood, PhD, Opentrons’ CEO, added “we made lab automation accessible for any lab, and our systems are built for AI to run experiments directly. That is why autonomous science is standardizing on Opentrons.”
Opentrons reports that to date, it has deployed over 11,000 robots to laboratories in over 80 countries. Its customer base includes academic groups, diagnostic labs, and global pharmaceutical companies, Earlier this year, the company announced that it is using Nvidia’s Isaac and Cosmos AI platforms to generate training data needed to develop and deploy physical AI-enabled laboratory robotics.
